Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.
about
NeuroblastomaAurora Kinase Inhibitors: Current Status and OutlookNew Auroras on the Roles of the Chromosomal Passenger Complex in Cytokinesis: Implications for Cancer TherapiesOptimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid LeukemiaA phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.Danusertib, an aurora kinase inhibitor.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicThe aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.Cell cycle control in acute myeloid leukemia.Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsThe potential role of Aurora kinase inhibitors in haematological malignancies.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluationA review of tumour lysis syndrome with targeted therapies and the role of rasburicase.Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.Novel therapies for children with acute myeloid leukaemia.Update on emerging treatments for chronic myeloid leukemia.Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Novel approaches to pediatric leukemia treatment.A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.Selection of cyclic-peptide inhibitors targeting Aurora kinase A: problems and solutions.Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.Acute myeloid leukaemia.Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.Theoretical Studies on Azaindoles as Human Aurora B Kinase Inhibitors: Docking, Pharmacophore and ADMET Studies.CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.
P2860
Q24617733-E83DCD90-6196-49CA-813D-661154688685Q26770583-96C35CA3-9D35-4661-8E85-D8C7D09D0019Q26777135-35B8BC06-175E-4DAA-89E4-E34EB373E891Q27674324-48FCB1C0-93A5-490F-95A7-B02A8E1C679BQ33167422-457BF8C1-3EE1-497D-A467-047BA53E0707Q33709521-DFB4F43B-AA5A-486B-B838-002112E39CEBQ33897070-0B8B2714-A9D9-43A7-B8EB-DEEF07953AF8Q34126899-A77EF3BA-1A12-46C2-B916-9FB471280819Q34817365-6492E4D1-DEAC-4F9A-A64F-1A0B936741EBQ34981765-676425F9-46DE-4B45-BAA5-A2C5CC3A2B3FQ34988013-C0E74899-ED17-4DE9-B081-04DA80CBD60FQ35210664-110BF979-AA47-4EDC-A59D-A9E7197A6B9DQ35740894-657A38AD-3F23-4150-97DB-BC0659605BE1Q35816817-8937C9AC-B703-4F4E-9342-38912A8F9520Q36002546-31DFEF7C-C8E4-4E70-848F-6DE69654CE5DQ36206479-993F5632-EBBA-4538-BF60-8D567DF127A0Q36469916-DEA7ECA1-0816-4EC9-A5F7-740599D810BBQ37167047-8E260571-C436-4909-B4EC-E338517B2089Q37643136-1E00D02A-382D-4B2B-AB1E-2FE84576A93CQ37699220-FCC72F3F-5BC8-402D-B0AC-DD5D8205B839Q37866341-01937065-49FA-4CA5-831A-EB49A1005510Q37876882-CBD27BC8-8DB7-4B4B-994E-3F466DDD53BFQ37994256-4ADDF02F-D207-44D2-A526-8ECCC405A23BQ38026453-DFAA7484-AEB8-4C15-9FF1-2D5D37457ED7Q38096798-F04B89A3-5F74-4F4F-B73F-2C3A2481AD8AQ38397515-8854C6FB-61CB-4C8E-86E6-45D4FDDE6B3EQ38401664-89E9D6A4-8755-4C97-82CC-E597174FFAE6Q38500371-64280702-B796-4661-AD00-4AAEB793521EQ38735991-D9E37DBF-E75C-4DC9-9E71-9A262734F7B9Q38788657-69E3A2A2-E706-4C7B-84CA-91DE0EECD480Q38913428-F18412E3-E7E1-461A-BBB8-2B1868E15E01Q39240059-4AA1DA43-9851-4FA7-8029-3E4CE1C71806Q46827793-CFE5BA58-01F6-421B-840C-A92135C77DD8Q47432401-6E4420D8-CA5F-4068-952F-125ED94250C2Q48213066-1DA6006A-6CC3-4D5D-B17C-C256503AB214Q52812759-846C740F-5C8F-4124-B08D-0B5E578BC97AQ53075287-A2DE14C3-25F1-4D84-8FBD-4E3DB593373AQ53088760-6A807C02-939C-49AE-B932-302F56E7910E
P2860
Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aurora kinase inhibitors: nove ...... iladelphia-positive leukemias.
@en
Aurora kinase inhibitors: nove ...... iladelphia-positive leukemias.
@nl
type
label
Aurora kinase inhibitors: nove ...... iladelphia-positive leukemias.
@en
Aurora kinase inhibitors: nove ...... iladelphia-positive leukemias.
@nl
prefLabel
Aurora kinase inhibitors: nove ...... iladelphia-positive leukemias.
@en
Aurora kinase inhibitors: nove ...... iladelphia-positive leukemias.
@nl
P2860
P356
P1433
P1476
Aurora kinase inhibitors: nove ...... hiladelphia-positive leukemias
@en
P2093
A D J Pearson
P2860
P2888
P304
P356
10.1038/LEU.2010.15
P577
2010-02-11T00:00:00Z